Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

3 years ago

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

3 years ago

Top-line data anticipated in the Q3 2022SAN DIEGO, May 23, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the…

Sientra To Present At The William Blair 42nd Annual Growth Stock Conference

3 years ago

SANTA BARBARA, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its…

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

3 years ago

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

NYMOX Receives RTF letter from FDA

3 years ago

IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a…

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

3 years ago

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that…

Catalyst Biosciences Sells Complement Portfolio for $60 Million

3 years ago

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has…

Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022

3 years ago

– Six abstracts presented highlighting data on BylvayTM(odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters –…

WIMI Hologram Academy: Psychological application of multi-perceptual interactive experience of virtual reality technology

3 years ago

HONG KONG, May 23, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors

3 years ago

Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates…